ALK-Abello's dust mite immunotherapy meets in second Phase III
ALK-Abello A/S (CSE:ALK-B) said once-daily HDM AIT for up to 18 months met the primary endpoint of reducing the risk of moderate to severe asthma exacerbations vs. placebo in the Phase III MITRA (MT-04) trial to treat house dust mite-induced allergic asthma (p<0.05). The double-blind, European trial enrolled 834 patients. MITRA is the second of two Phase III trials of the product conducted by ALK-Abello to treat house dust mite-induced respiratory diseases. Last month, the company reported data from the Phase III MERIT (MT-06) trial showing once-daily HDM AIT for one year met the primary endpoint in patients with house dust mite-induced allergic rhinitis (see BioCentury, June 19).
ALK-Abello plans to submit a European regulatory application for HDM AIT, a tablet-based vaccine against biological house dust mite allergen, in 2014. ALK-Abello gained DKK9 to DKK452 on Thursday. ...